rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KNSA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

      LONDON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 11:00 a.m. Greenwich Mean Time (6:00 a.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kini

      Nov 11Yahoo FinanceKNSAJEF
      Kiniksa Pharmaceuticals stock hits all-time high of 98.49 USD
      Nov 9Investing.comKNSA
      Kiniksa (KNSA) Stock Jumps As Q3 Results Fuel Growth Debate
      Oct 28Yahoo FinanceKNSA
      Kiniksa Pharmaceuticals International PLC (KNSA) (Q3 2026) Earnings Call Highlights: ARCALYST ...
      Oct 28Yahoo FinanceKNSA
      Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
      Oct 27Yahoo FinanceKNSA
      Kiniksa Pharmaceuticals, Ltd. Q3 2026 Earnings Call Summary
      Oct 27Yahoo FinanceKNSA
      12 Health Care Stocks Moving In Tuesday's Intraday Session
      Oct 27BenzingaKNSA
      Crude Oil Moves Lower; Corning Earnings Top Views
      Oct 27BenzingaKNSAGLW
      Kiniksa Pharms earnings beat by $0.19, revenue topped estimates
      Oct 27Investing.comKNSA
      What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
      Oct 27Yahoo FinanceKNSA
      Kiniksa Pharmaceuticals stock hits all-time high of 84.51 USD
      Oct 27Investing.comKNSA
      Kiniksa Q3 2026 slides: ARCALYST revenue tops $1B guidance milestone
      Oct 27Investing.comKNSA
      Kiniksa Pharmaceuticals Q3 2026 Earnings Call Transcript
      Oct 27BenzingaKNSA
      Kiniksa Pharmaceuticals' Q3 Net Income, Revenue Rise; Shares Up Pre-Bell
      Oct 27Yahoo FinanceKNSA
      Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
      Oct 27Yahoo FinanceKNSA
      Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution

      – ARCALYST® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion –– KPL-387 pivotal Phase 3 data expected in 2H 2027 –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for

      Oct 27Yahoo FinanceKNSA
      Kiniksa Pharmaceuticals earnings in focus amid growth surge
      Oct 26Investing.comKNSA
      Kiniksa Pharmaceuticals appoints Ross Moat as president and COO, updates compensation
      Oct 22Investing.comKNSA
      Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
      Oct 22Yahoo FinanceKNSA
      Major Indexes Test Resistance; Lindblad, Kiniksa Pharma, Guidewire In Focus - Video - IBD
      Oct 20Investor's Business DailyKNSALINDGWRE
      Kiniksa Pharmaceuticals stock hits all-time high at 82.96 USD
      Oct 15Investing.comKNSA
      Biotech Watch: Regeneron Partner Has Breakout In Sight

      Regeneron partner Kiniksa stands among the top biotech stocks to watch.

      Oct 14Investor's Business DailyKNSAREGN
      Kiniksa Pharmaceuticals Has Strong Growth And Little Room For Disappointment (NASDAQ:KNSA)

      Kiniksa Pharmaceuticals has a high share price and insufficient margin of safety despite strong ARCALYST commercial execution. Learn why KNSA stock is a hold.

      Oct 2Seeking AlphaKNSA
      Kiniksa Pharmaceuticals International (KNSA) On The ARCALYST Story And Whether Shares Look Fully Valued

      Kiniksa Pharmaceuticals International (KNSA) has drawn fresh attention after recent share performance data highlighted sharp swings, with the stock down about 4% over the past month but up roughly 34% in the past 3 months. Short term momentum for Kiniksa Pharmaceuticals International has cooled a little, with the share price down over the past month. However, the 90 day share price return of 33.73% and year to date gain of 81.12% point to a strong upswing overall. Compare Kiniksa...

      Sep 23Yahoo FinanceKNSA
      Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

      KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.

      Sep 17Yahoo FinanceKNSA
      Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat

      Biotech leader Kiniksa stock is poised to hit a new buy point after shares soared 25% in response to better-than-expected sales numbers.

      Sep 10Investor's Business DailyKNSA
      Kiniksa at Wells Fargo conference: arcalyst growth and pipeline deepen
      Sep 9Investing.comKNSAWFC
      Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

      LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximate

      Sep 4Yahoo FinanceKNSA
      Three Biotech Stocks Stick Out With Their Stellar Charts

      These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

      Aug 21Investor's Business DailyETONKNSATVTX
      Massive Sales Are Expected To Drop — It's All According To Plan

      Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining. But the company has a plan.

      Aug 21Investor's Business DailyKNSA

      This is the newest page. Registered accounts read further back.